中药联合化疗治疗卵巢癌的文献研究

发布时间：2018-07-16 16:53

【摘要】：卵巢癌是妇科常见的恶性肿瘤,发病率高,预后差,多数患者发现时已是晚期,卵巢癌目前公认的治疗方法是肿瘤细胞减灭手术配合化疗。手术是一个损伤正气的过程,而化疗药物作用于肿瘤细胞的同时对正常细胞也有毒性作用,引起相应的毒副反应,主要表现有骨髓抑制、消化道反应、神经毒性等,使机体难以耐受甚至不得不中断治疗。近年来,中医中药相关治疗的研究也越来越多,在治疗肿瘤化疗后的毒副反应上有一定疗效,能够帮助机体提高免疫力,更好的配合治疗。就近几年中医在治疗卵巢癌术后化疗后的临床研究上,本文对其作了一个文献型研究。目的：通过对近年有关中医治疗卵巢癌术后化疗后的文献进行研究,探讨中医对卵巢癌术后化疗后病机的认识,以及中药治疗的用药规律。方法：以CNKI知识数据库、万方数据知识平台、维普中文科技期刊数据库为检索工具,搜索1990年1月至2014年2月有关卵巢癌的中医临床研究文献,筛选出中医结合卵巢癌化疗的临床文献。对文献中所用的中药以类别、功效、性味、归经、频率等内容建立数据库,运用Excel软件建立数据库并进行分类统计。结果：根据资料来源及检索方法,共获得124篇文献,依照本文前面所述纳入标准,筛选出符合标准的文献27篇,所有文献中涉及病例数1201例,收集方剂共35首,所用药物116味,药物共出现410次,所使用次数14225人次。 1.根据文献中出现的证型看,卵巢癌术后化疗后患者以气阴两虚型最多,达35.22%,其次是气虚血瘀型21.4%,脾虚湿困型17.24%。 2.根据所使用药物频率得出,药物使用率排名前10位依次为黄芪、白术、茯苓、党参、甘草、白花蛇舌草、半枝莲、当归、薏苡仁、莪术。 3.根据药物归类看,药物出现次数最多的为补虚药,占38.29%；其次是清热药,占15.61%；活血化瘀药占12.93%。 4.根据药物药性及归经看,出现最多的药性为平性药,药味为甘味,归经最多的为脾经。结论：卵巢癌术后化疗后以虚证为多,治疗以补虚为主,清热解毒、活血化瘀为辅。
[Abstract]:Ovarian cancer is a common gynecological malignant tumor with high incidence and poor prognosis. Surgery is a process of damage to qi, and chemotherapy drugs also have toxic effects on normal cells when they act on tumor cells, causing the corresponding toxic and side effects, such as bone marrow suppression, digestive tract reaction, neurotoxicity and so on. Make the body difficult to tolerate or even have to interrupt treatment. In recent years, there are more and more researches on TCM related treatment, which has a certain curative effect on the side effects of tumor chemotherapy, which can help the body to improve immunity and better cooperate with treatment. In this paper, a literature study on the treatment of ovarian cancer after chemotherapy was carried out in this paper. Objective: to study the literature on the treatment of ovarian cancer by traditional Chinese medicine (TCM) after chemotherapy in recent years, and to explore the understanding of the pathogenesis of postoperative chemotherapy of ovarian cancer and the rule of traditional Chinese medicine (TCM) in the treatment of ovarian cancer. Methods: using CNKI knowledge database, Wanfang data knowledge platform and Weipu Chinese science and technology periodical database as the retrieval tools, we searched for the literature of TCM clinical research on ovarian cancer from January 1990 to February 2014. The clinical literature of Chinese medicine combined with ovarian cancer chemotherapy was screened out. The database of traditional Chinese medicine used in literature was established with the contents of category, efficacy, sexual taste, meridian, frequency and so on. The database was established by using Excel software and classified statistics were carried out. Results: according to the data sources and retrieval methods, a total of 124 articles were obtained. According to the inclusion criteria mentioned in the previous article, 27 articles were selected to meet the criteria. 1201 cases were involved in all the literatures, 35 prescriptions were collected and 116 kinds of drugs were used. The drug appeared 410 times, the number of times used was 14225. 1. According to the syndrome types appeared in the literature, the most of the patients with ovarian cancer after chemotherapy were deficiency of Qi and Yin (35.22), followed by deficiency of Qi and Blood stasis (21.442), spleen deficiency of dampness (17.2442) and stagnation of dampness (17.24.2). According to the frequency of the drugs used, the top 10 places of drug use rate were Astragalus, Atractylodes macrocephala, Poria cocos, Codonopsis, Glycyrrhiza, Scutellaria barbata, Angelica sinensis, Coix seed, Curcuma. According to the classification of drugs, the most frequent occurrence of drugs was deficiency drugs (38.29), followed by heat-clearing drugs (15.61%) and blood circulation drugs (12.933.4%). According to the medicinal properties and classics, the most common drugs were flat drugs, sweet taste and spleen meridian. Conclusion: deficiency syndrome is the main treatment for ovarian cancer after chemotherapy, the main treatment is tonifying deficiency, clearing heat and detoxifying, activating blood circulation and removing blood stasis.
【学位授予单位】：北京中医药大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.31

【参考文献】